Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece

Background: Non-small cell lung cancer (NSCLC), which accounts for about 80%-85% of lungcancer cases, is a leading cause of cancer-related death worldwide. Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of patients with advanced, ALK-pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Gourzoulidis, George, Zisimopoulou, Oresteia, Boubouchairopoulou, Nadia, Michailidi, Christina, Lowry, Chrissy, Tzanetakos, Charalampos, Kourlaba, Georgia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853822/
https://www.ncbi.nlm.nih.gov/pubmed/35620456
http://dx.doi.org/10.36469/jheor.2022.32983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853822/
https://www.ncbi.nlm.nih.gov/pubmed/35620456
http://dx.doi.org/10.36469/jheor.2022.32983

Ejemplares similares